1. Home
  2. CBC vs SRRK Comparison

CBC vs SRRK Comparison

Compare CBC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBC

Central Bancompany Inc.

N/A

Current Price

$29.48

Market Cap

6.4B

Sector

N/A

ML Signal

N/A

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$53.77

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBC
SRRK
Founded
1902
2012
Country
United States
United States
Employees
3036
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CBC
SRRK
Price
$29.48
$53.77
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$28.67
$56.17
AVG Volume (30 Days)
792.5K
1.2M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
2.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.15
N/A
Revenue Next Year
$6.34
$534.24
P/E Ratio
$14.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.50
$27.07
52 Week High
$29.92
$53.86

Technical Indicators

Market Signals
Indicator
CBC
SRRK
Relative Strength Index (RSI) 62.68 69.08
Support Level $26.86 $45.46
Resistance Level N/A N/A
Average True Range (ATR) 0.85 2.24
MACD 0.06 1.02
Stochastic Oscillator 85.11 86.85

Price Performance

Historical Comparison
CBC
SRRK

About CBC Central Bancompany Inc.

Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Share on Social Networks: